According to the company, its focus on therapeutics that target the epithelial-mesenchymal transition (EMT) in cancer supports the development of BGB324.
BerGenBio CEO Richard Godfrey said inhibition of the EMT process can delay or prevent metastasis, overcome and even reverse drug resistance as well as prevent cancer recurrence.
"Our development plan for BGB324 aims to initiate Phase I clinical studies by the end of 2012," Godfrey added.